

A list of all abbreviations and terms appearing in this issue of *Therapy*

3TC	Lamivudine	IFN- $\gamma$	Interferon- $\gamma$
5ARI	5 -reductase inhibitor	IgG	Immunoglobulin G
ABC	Abacavir	im.	Intramuscular
ACS	Acute coronary syndrome	INR	International Normalized Ratio
ADEM	Acute disseminated encephalomyelitis	IPSS	International Prostate Symptom Score
AF	Atrial fibrillation	iv.	Intravenous
ALT	Aminotransferase	LFT	Liver function test
ANA	Antinuclear antibody	LPV/r	Lopinavir/ritonavir
ANOVA	Analysis of variance	LUTS	Lower urinary tract symptom
API	Active pharmaceutical ingredient	MOG	Myelin oligodendrocyte glycoprotein
aPTT	Activated partial thromboplastin time	MS	Multiple sclerosis
ARR	Annualized relapse rate	MSFC	Multiple Sclerosis Functional Composite
ARV	Antiretroviral drug	N/M	Not measured
AUC	Area under the plasma concentration curve	NACO	National AIDS Control Organization
AVP	8-arginine vasopressin	NC	Normal control
AZT	Zidovudine	NEPAD	New Partnership for Africa's Development
b.i.d.	Twice-daily	NK	Natural killer
BFLUTS	Bristol female LUTS	NMO	Neuromyelitis optica
BISTRO I	Boehringer Ingelheim Study in Thrombosis	NMSS	National Multiple Sclerosis Society
BPO	Benign prostatic obstruction	NVP	Nevirapine
CADASIL	Cerebral autosomal dominant arteriopathy	o.d.	Once-daily
CBC	Complete blood cell count	OAB	Overactive bladder
CHAI	Clinton Foundation HIV/AIDS Initiative	OASIS	Old astrocyte specifically induced substance
CIS	Clinically isolated syndromes	OD	Optical density
CL	Compulsory license	OPC	Oligodendrocyte progenitor cells
CLCR	Creatinine clearance	OPTION	Tocilizumab Pivotal Trial in Methotrexate Inadequate Responders
C <sub>max</sub>	Maximum plasma concentration	PBS	Phosphate-buffered saline
CMC	Carboxymethylcellulose sodium	PE	Pulmonary embolism
CRP	C-reactive protein	PETRO	Prevention of Embolic and Thrombotic Events in Patients with Persistent AF
CSF	Cerebrospinal fluid	P-gp	P-glycoprotein
CSZ	<i>Cornus officinalis</i> Sieb. et Zucc.	PML	Progressive multifocal leukoencephalopathy
CV	Coefficient of variation	PMTCT	Prevention mother-to-child transmission
CYP	Cytochrome P450	PPMS	Primary progressive
D4T	Stavudine	PT	Prothrombin time
DDAVP	1-desamino-8-D-arginine vasopressin acetate	QoL	Quality of life
DM	Diabetes mellitus	R	Response
DMARD	Disease-modifying antirheumatic drug	RA	Rheumatoid arthritis
DMT	Disease-modifying therapy	RE-DEEM	Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
DSMB	Data safety monitoring board	RE-LY	Randomized Evaluation of Long-term anticoagulant therapy
DTI	Direct thrombin inhibitor	Rf	Retention factor
DVT	Deep-vein thrombosis	RRMS	Relapsing–remitting MS
EAE	Experimental autoimmune encephalomyelitis	RSD	Relative standard deviation
EB	Ethidium bromide	s.c.	Subcutaneous
ECOWAS	Economic Community of West African States	SAA	Serum amyloid A
ECT	Ecarin clotting time	SAMURAI	Study of Active Controlled Monotherapy for Rheumatoid Arthritis, an IL-6 Inhibitor
EDSS	Expanded Disability Systems Scale	SCGE	Single-cell gel electrophoresis
EFV	Efavirenz	SE	Standard error
ER	Endoplasmic reticulum	SFDA	State Food and Drug Administration
ERAD	ER-associated degradation	SPMS	Secondary progressive
ERSR	ER stress response pathway	SR	Sustained release
ESR	Erythrocyte sedimentation rate	SSRIs	Selective serotonin reuptake inhibitors
FDC	Fixed-dose combination	TDF	Tenofovir
FSS	Fatigue severity scale	THR	Total hip replacement
FTC	Emtricitabine		
FVC	Frequency/volume chart		
GA	Glatiramer acetate		
GPO	Government Pharmaceutical Organization		
ICIQ-N	Incontinence Questionnaire for Nocturia		

## GLOSSARY

TKR	Total knee replacement	USC	University of Southern California
TLC	Thin layer chromatography	VKA	Vitamin K antagonist
TRIPS	Trade-Related Aspects of Intellectual Property Rights	VL	Voluntary license
TSH	Thyroid-stimulating hormone	VTE	Venous thromboembolism
TT	Thrombin clotting time	WTO	World Trade Organization
UA	Ursolic acid		
UPR	Unfolded protein response		